Vaccitech reports Q3 EPS 22c, consensus (33c)

Reports Q3 revenue $6.2M, consensus $7.82M. As of September 30, the company’s cash and cash equivalents were $200.1M, compared to $214.1M as of December 31, 2021. Vaccitech said, "We have made excellent progress in our clinical programs in the past quarter and expect to reach a number of important clinical milestones in 2023. We expect to have initiated our Phase 1/2a clinical study in the fourth quarter of 2022 with the first patient first visit (FPFV) for VTP-850, our prostate cancer program, early in the first quarter of 2023, and FPFV for VTP-1100, our HPV-Cancer program, early in the third quarter of next year. FPFV for VTP-1000, our program in Celiac disease, is slated for the fourth quarter of 2023. We also plan to present data from multiple ongoing studies of VTP-300 in HBV next year as well. So, we are looking forward to a 2023 filled with exciting clinical advances."